VECT - Dosing underway in VectivBio's mid-stage apraglutide study in short bowel syndrome

VectivBio Holding ([[VECT]] +1.9%) has dosed the first patient in its Phase 2 STARS Nutrition metabolic balance study evaluating apraglutide in colon-in-continuity ((CIC)) patients with short bowel syndrome with intestinal failure (SBS-IF). This Phase 2 trial is designed to evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in SBS-IF CIC patients.The trial is expected to enroll approximately 10 patients and will measure their calorie absorption at weeks 4 and 48.Secondary endpoints will assess changes in parenteral support volume.The initial readout of 4-week absorption data is expected in H1 2022.

For further details see:

Dosing underway in VectivBio's mid-stage apraglutide study in short bowel syndrome